Invention Grant
US08444965B2 Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
有权
来自免疫特异位点的肿瘤细胞作为基于细胞的癌症疫苗的基础细胞
- Patent Title: Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
- Patent Title (中): 来自免疫特异位点的肿瘤细胞作为基于细胞的癌症疫苗的基础细胞
-
Application No.: US12889043Application Date: 2010-09-23
-
Publication No.: US08444965B2Publication Date: 2013-05-21
- Inventor: Suzanne Ostrand-Rosenberg , Jacobus J. Bosch , Bruce R. Ksander
- Applicant: Suzanne Ostrand-Rosenberg , Jacobus J. Bosch , Bruce R. Ksander
- Applicant Address: US MD Baltimore
- Assignee: University of Maryland, Baltimore County
- Current Assignee: University of Maryland, Baltimore County
- Current Assignee Address: US MD Baltimore
- Agency: Moore & Van Allen, PLLC
- Agent Marianne Fuierer
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C12N5/0783 ; C12N5/09 ; C12N15/00 ; C12N15/867 ; C12N15/87
Abstract:
The present invention relates to tumor cell-based vaccines and methods of using same, wherein the vaccines are based on naturally immune privileged tumor cells that have been genetically modified to express MHC-II restricted peptides derived from endogenously encoded tumor antigens, activate CD4+ T-lymphocytes, provide an array of antigens to which the host is not tolerized and/or induce immunity against the originating tumor cells as well as against metastatic tumor cells.
Public/Granted literature
- US20110165187A1 TUMOR CELLS FROM IMMUNE PRIVILEGED SITES AS BASE CELLS FOR CELL-BASED CANCER VACCINES Public/Granted day:2011-07-07
Information query
